For decades, substance use disorder (SUD) treatment has been managed as an episodic crisis. A patient arrives in acute withdrawal, receives medically supervised detoxification, and is discharged — often with little continuity of care and no long-term clinical management plan. The healthcare system has largely treated addiction as a behavioral failing rather than a chronic, medically complex condition. That framing is shifting, and the implications for health plans, third-party administrators (TPAs), employers, and utilization management (UM) programs are significant.
The emerging clinical consensus positions SUD alongside conditions like diabetes, hypertension, and heart disease: a chronic illness that requires ongoing medical management, evidence-based intervention, and coordinated care across multiple specialties. For health plans and TPAs, this reframing demands a parallel evolution in how UM programs evaluate appropriate levels of care. The gap between where SUD treatment is heading and how most UM programs are currently designed represents both a clinical risk and a financial one.
The Gap Between SUD Care Reality and UM Practice
The American Society of Addiction Medicine (ASAM) Criteria, 4th Edition (published December 2023), organizes SUD treatment into four broad levels of care: Level 1 (Outpatient), Level 2 (Intensive Outpatient), Level 3 (Residential), and Level 4 (Medically Managed Inpatient). Within each level, decimal gradations reflect increasing clinical intensity, with the medically managed sub-levels — 2.7, 3.7, and 4 — representing the points on the continuum where active withdrawal management and biomedical monitoring are required. Yet despite this well-established framework, UM programs often default to binary thinking: inpatient withdrawal management or not, residential or outpatient.
The data illustrates both the scale and the shifting complexity of the challenge. According to the 2024 National Survey on Drug Use and Health (NSDUH), published by SAMHSA in July 2025, an estimated 48.4 million people in the U.S. — roughly 16.8% of the population aged 12 or older — met criteria for a substance use disorder in 2024. Yet 80% of those who needed treatment did not receive it. Among those who do enter the treatment system, the stakes of appropriate level of care placement are high. This is especially true as SUD presentations grow more medically complex: polysubstance use, alcohol-related hepatic disease, opioid use disorder with cardiac and pulmonary complications, and stimulant use with psychiatric comorbidities are increasingly common clinical presentations that demand more from UM review, not less.
Health plans and TPAs face a dual risk when UM programs are not calibrated to this complexity:
- Overutilization: Patients placed at higher levels of care than clinical evidence supports, driving avoidable inpatient costs and occupying limited beds needed by patients who genuinely require that level of care.
- Underutilization: Patients stepped down prematurely without clinical basis, increasing the likelihood of relapse, readmission, and higher total cost of care over time.
The regulatory landscape reinforces the need for rigor. While all U.S. states have enacted statutes addressing mental health and SUD insurance parity, the strength and scope of these laws vary widely. State insurance commissioners are increasingly scrutinizing how health plans apply UM criteria to behavioral health relative to medical and surgical benefits, and the data in the Mental Health and SUD Insurance Parity Summary of State Laws demonstrates that most states have enacted or are actively writing legislation to strengthen parity protections. For health plans operating across multiple states, the compliance picture is not uniform, and that makes evidence-based, consistently applied clinical review all the more critical.
Evidence-Based Reviews Across the SUD Continuum
Accurate SUD level-of-care determination requires more than criteria matching. Clinical nuance is high: withdrawal severity, substance type, prior treatment history, co-occurring medical and psychiatric conditions, and social determinants of health all inform appropriate level of care (LOC) in ways that algorithmic review cannot reliably capture. Physician-led review, conducted by specialists with direct clinical experience in addiction medicine, is essential.
MRIoA’s clinical review capabilities span the full SUD continuum, ranging from Level 1 (Outpatient) through Level 4 (Medically Managed Inpatient), including the clinical intensity within those levels. Appropriate level of care placement is not a one-time determination; the ASAM framework calls for ongoing reassessment as a patient’s clinical status evolves, with the goal of stepping down to the least intensive setting that safely supports recovery.
The integrated treatment dimension matters here as well. MRIoA’s reviewer network includes addiction psychiatrists alongside internists, hepatologists, cardiologists, and other medical specialists. As SUD presentations increasingly intersect with complex medical conditions, the ability to bring multi-specialty clinical input to a single review becomes a meaningful differentiator. The growing clinical evidence base for medication-assisted treatment (MAT) also means that pharmacy-related reviews, MAT appropriateness, and concurrent medical management are becoming standard components of UM for SUD.
MRIoA’s Capabilities for SUD and Detox Review
MRIoA brings specialized depth to SUD clinical review that general UM programs cannot replicate:
- Addiction psychiatry expertise at the intersection of SUD and medical management, drawing from a panel of 40+ behavioral health specialists who bring direct clinical experience to complex, comorbid presentations.
- Defensible, criteria-grounded determinations using ASAM, InterQual, MCG, or client-specified criteria, applied by physicians with hands-on addiction medicine experience — not algorithmic matching.
- Same-day review capability that meets the clinical urgency inherent in detox presentations, where level-of-care decisions must be made quickly and accurately.
- State-matched reviewer licensing across all 50 states, which is particularly important for Medicaid SUD programs operating under state-specific utilization review requirements.
Matching Clinical Review to the Complexity of SUD
As SUD treatment evolves toward integrated, chronic disease management, health plans and TPAs need a clinical review partner whose expertise matches the complexity of the cases they are seeing. Getting level of care right in SUD is not primarily a cost management exercise. It is a clinical quality imperative that directly affects members’ recovery outcomes, long-term total cost of care, and compliance with evolving regulations.
MRIoA’s detox and SUD level of care review capabilities are purpose-built for this moment, grounded in 40+ years of clinical review experience and backed by physician specialists who bring real addiction medicine expertise to every case.
Schedule a consultation to learn how MRIoA can help your organization ensure appropriate, evidence-based care decisions for every member.
